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Background: A nanoscale injectable in situ-forming hydrogel drug delivery system was 
  developed in this study. The system was based on a self-assembling peptide RADA16 solu-
tion, which can spontaneously form a hydrogel rapidly under physiological conditions. We 
used the RADA16 hydrogel for the controlled release of paclitaxel (PTX), a hydrophobic 
antitumor drug.
Methods: The RADA16-PTX suspension was prepared simply by magnetic stirring, followed 
by atomic force microscopy, circular dichroism analysis, dynamic light scattering, rheological 
analysis, an in vitro release assay, and a cell viability test.
Results: The results indicated that RADA16 and PTX can interact with each other and that the 
amphiphilic peptide was able to stabilize hydrophobic drugs in aqueous solution. The particle 
size of PTX was markedly decreased in the RADA16 solution compared with its size in water. 
The RADA16-PTX suspension could form a hydrogel in culture medium, and the elasticity of 
the hydrogel showed a positive correlation with peptide concentration. In vitro release measure-
ments indicated that hydrogels with a higher peptide concentration had a longer half-release 
time. The RADA16-PTX hydrogel could effectively inhibit the growth of the breast cancer cell 
line, MDA-MB-435S, in vitro, and hydrogels with higher peptide concentrations were more 
effective at inhibiting tumor cell proliferation. The RADA16-PTX hydrogel was effective at 
controlling the release of PTX and inhibiting tumor cell growth in vitro.
Conclusion: Self-assembling peptide hydrogels may work well as a system for drug delivery.
Keywords: self-assembling peptide, hydrogel, paclitaxel, drug delivery, antitumor
Introduction
Paclitaxel (PTX) is one of the most effective antitumor drugs found in nature in the 
past few decades.1,2 It promotes polymerization of tubulin dimers, which results in the 
formation of highly stable nonfunctional microtubules in the absence of guanosine 
triphosphate and microtubule-associated proteins, ultimately preventing cell division.3,4 
Because of its unique mechanism of action against tumor cells, PTX has demonstrated 
excellent therapeutic efficacy for a wide range of cancers, although it works especially 
well for treatment of ovarian and breast cancers.1
Paclitaxel is hydrophobic and is poorly soluble in water. Currently, the PTX used 
clinically is in a vehicle composed of Cremophor® EL and ethanol at a 50:50 (v/v) 
ratio. Cremophor EL is a nonionic polyethoxylated castor oil solubilizer that can 
enhance PTX solubility. However, this solvent causes severe hypersensitive reactions 
and cytotoxicity and is incompatible with polyvinyl chloride, which is commonly used 
in injection systems.2,5 In addition, PTX can cause serious side effects at   excessive International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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doses, such as bone marrow suppression and cardiac rhythm 
disturbances.3 Therefore, researchers have developed a 
variety of vehicles, including microspheres, nanoparticles, 
surgical pastes, polymeric micelles, and hydrogels, to control 
PTX release and to eliminate the toxicity of Cremophor EL 
to the body.1,3
Hydrogels have been commonly used in drug delivery, and 
various natural polymers and synthetic copolymer hydrogels, 
such as chitosan, hyaluronic acid, alginate, polymethyl meth-
acrylate, and polyethylene glycol, have been studied. These 
compounds usually form hydrogel-drug complexes outside 
of the body and are then delivered into the body.5–9 However, 
the formation of hydrogels frequently involves ultraviolet 
photopolymerization and various chemical cross-linking 
techniques, and there is a potential risk that toxic reagents may 
fail to be removed completely prior to hydrogel implantation. 
Furthermore, some hydrogels have high elasticity, which 
generally prevents their extrusion through a syringe needle.6 
Therefore, an alternative vehicle is necessary.
Self-assembling peptides are a type of designed bioma-
terial and have been used in a number of biomedical appli-
cations, such as cell culture, tissue engineering, and drug 
delivery.10–13 Self-assembling peptides can spontaneously 
assemble to cross-linked nanofibers of 10–20 nm in diameter 
and form a stable second structure of β-sheet in aqueous 
solution. Under physiological conditions, the peptide solu-
tion can rapidly self-assemble into hydrogels, which contain 
more than 99% (w/v) water.11,12,14 Previous studies have used 
RADA16 peptide to slow the release of proteins and local-
ized therapies through injection into a particular tissue.15–18 
Because the process of hydrogel formation is ionic-dependent 
and is irrelevant with ultraviolet or chemical cross-linking, 
it was supposed that RADA16 may serve well as a potential 
drug delivery vehicle.
The purpose of this study was to develop an injectable 
in situ gel drug delivery system based on a self-assembling 
peptide. The incorporation of peptide and drug was achieved 
simply by mix and magnetic stirring. To investigate the inter-
action of RADA16-PTX, the release properties of hydrogel, 
and antitumor efficiency in the current study, we performed 
a morphology analysis, circular dichroism, dynamic light 
scattering, rheological test, in vitro release test, and a cell 
viability test.
Materials and methods
Incorporation of peptide and PTX
Self-assembling peptide RADA16 (n-RADARADARA-
DARADA-c) was commercially synthesized and purified 
by Shanghai Biotech Bioscience and Technology Co Ltd 
(Shanghai, China). Paclitaxel was purchased from the 
National Institute for the Control of Pharmaceutical and 
Biological Products (Beijing, China). Peptide solutions at 
concentrations of 5 and 10 mg/mL were prepared by dis-
solving RADA16 peptide powder in Milli-Q water with 
10 minutes of sonication. The peptide solution incorporated 
with PTX was prepared by adding peptide solution (5 or 
10 mg/mL) into a glass vial with PTX at a final concentra-
tion of 1 mg/mL, followed by magnetic stirring for 48 hours, 
whereas the control sample was formed by adding Milli-Q 
water instead of peptide solution. All of the vials and solvents 
were sterilized, and the samples were prepared in a biologi-
cal safety cabinet to avoid possible contamination for cell 
culture experiments.
Atomic force microscopy
The morphology of samples was observed using an atomic 
force microscope (SPI4000 Probe Station, Seiko Instru-
ments Inc, Chiba, Japan) with a tapping mode. For the 
preparation of the samples, RADA16 solution or RADA16-
PTX suspension was diluted 50 times in Milli-Q water, 
and then 10 µL of diluted solution was evenly placed on a 
freshly cleaved mica substrate. The mica surface was then 
rinsed with Milli-Q water to remove unattached peptide 
and air-dried. The measurement was performed at room 
temperature and all images were recorded with a resolution 
of 512 × 512 pixels. The typically scan parameters were 
set as follows: scan speed 1.00 Hz, amplitude 1–1.2 V, and 
integral and proportional gains of 0.2–0.3 and 0.03–0.04, 
respectively.
Dynamic light scattering
The particle size distribution of the RADA16 solution and 
RADA16-PTX suspension was investigated on a Nano-
Particle Size Analyzer (LB-550, Horiba Ltd, Kyoto, Japan) 
with appropriate viscosity and refractive index settings, and 
the temperature was maintained at 25°C during measurement. 
The RADA16 solution and RADA16-PTX suspension was 
diluted 20 times with Milli-Q water, and each sample was 
tested at least three times to generate the intensity-based size 
distribution plot report.
circular dichroism spectroscopy
The circular dichroism measurement was performed at 25°C 
on an Aviv Model 400 (Aviv Biomedical Inc,   Lakewood, 
NJ) with a 2 mm path length quartz cuvette. All samples 
of RADA16 solution and RADA16-PTX   suspension were International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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diluted 50 times with Milli-Q water before the test, and 
then circular dichroism spectra were collected at 1 nm 
intervals and 1 nm bandwidths from 190 to 260 nm, with 
three time scans for the average. All spectra were corrected 
by subtracting the baseline, and the data were expressed as 
molar ellipticity [θ] with units of deg ⋅ cm2 ⋅ dmol/L. The 
secondary structure fractions of the peptide were calculated 
by free software CDPro using a modified Contin method 
(CONTINLL program) and comparison with a set of refer-
ence proteins.
rheological analysis
The rheological properties of RADA16-PTX suspension 
were measured on a rheometer (AR2000, TA Instruments, 
New Castle, DE) with a 20 mm diameter and a 1° steel cone 
with 25 µm truncation gap. A 70 µL sample of RADA16-PTX 
suspension was placed on the plate of the rheometer and a 
trap was placed around the cone to seal the liquid. The stor-
age (G′) and loss (G″) modulus was measured at 37°C, and 
the parameters used for the frequency sweep tests were strain 
0.5% and frequency range 0.01–100 rad/sec. For rheological 
testing of peptide-PTX hydrogel, RADA16-PTX suspen-
sion was first induced to gel by adding 70 µL of phosphate-
buffered saline solution. After equilibrating for one minute, 
the excess solution was taken off, and the measurement was 
performed as described above.
In vitro release measurement
The release of PTX from RADA16-PTX hydrogel was 
carried out in vitro in phosphate-buffered saline solution. 
RADA16-PTX suspension 100 µL was dripped to the bottom 
of a cuvette, then 10 mL 0.1 M phosphate-buffered saline 
(pH 7.4) with 0.3% (w/v) sodium dodecyl sulfate was added 
gently and incubated at 37°C for an indicated time period. 
The concentration of PTX in phosphate-buffered saline was 
determined by reversed-phase high-pressure liquid chroma-
tography, performed with a Shimadzu LC-20 A high-pressure 
liquid chromatography system (Shimadzu Corporation, 
Kyoto, Japan). The mobile phase consisted of methanol and 
water (70:30). The injection volume was 20 µL and the mobile 
phase flow rate was 1.0 mL/min. Separation was achieved 
by a C-18 column (Shim-pack VP-ODS, 150 mm × 4.6 mm, 
5 µm). The column eluate was monitored at a wavelength 
of 227 nm. A calibration curve of PTX was constructed to 
determine the percentage of PTX released from the peptide 
hydrogel. At the end of the release test, the supernatant in 
the release medium was collected and measured by atomic 
force microscopy.
In vitro antitumor cell study
The human breast cancer cell line MDA-MB-435S was 
used for the in vitro cell viability study. The cells were 
cultured in L-15 medium containing 10% fetal bovine 
serum at 5% CO2. When cells reached 85% confluence, 
they were detached from cell culture flasks with trypsin 
and resuspended in cell culture medium at a concentration 
of 105 cells/mL. After 200 µL of the cell suspension was 
added to each well of a flat-bottom 96-well plate and incu-
bated overnight, the culture medium was removed. Twenty 
microliters of diluted PTX (Taiji Pharmaceutical Co Ltd, 
Sichuan, China), RADA16, or RADA16-PTX suspension 
was then pipetted into the central bottom of the well and 
equilibrated with 200 µL of culture medium to initiate 
peptide gel formation. The culture medium for all groups 
was changed daily. The cell viability assay was carried out 
at prearranged times.
Cell viability was estimated using a modified MTT assay 
in this study. Briefly, at different time points, 200 µL of 
serum-free medium and 20 µL of MTT solution (5 mg/mL 
in phosphate-buffered saline) were added to each sample, 
followed by incubation at 37°C for four hours to allow 
MTT formazan formation. The medium was then removed, 
and the converted dye was dissolved with 200 µL of 10% 
sodium dodecyl sulfate in 0.01 M HCl. After all crystals 
were solubilized, the optical density of the solution was 
determined at 570 nm against an sodium dodecyl sulfate 
solution blank using an enzyme-linked immunosorbent 
assay plate reader. Four parallel replicates were read for 
all samples. Cell viability was calculated by the following 
equation:
  Cell viability (%) = (Abstest cells/Abscontrol cells) × 100% 
in which Abstest cells and Abscontrol cells were the absorbencies 
of cells with different treatments and cells incubated with 
medium only, respectively.
Cell viability was also assessed by a Live/Dead assay. 
A work solution containing both 1 µM calcein AM and 
2 µM ethidium homodimer in phosphate-buffered saline 
were prepared according to the Live-Dead assay (Molecular 
Probes®, Invitrogen, Carlsbad, CA) package instructions, and 
200 µL of work solution was added to each well. All cells 
were imaged using a fluorescence microscope.
statistical analysis
All quantitative data were shown as the mean ± standard 
deviation. Statistical analysis was performed using SPSS International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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software (version 11.5, Chicago, IL) with one-way analysis 
of variance and a 95% confidence level.
Results and discussion
Interaction of rADA16 and PTX
The self-assembling RADA16 peptide is a designed nano-
scale biomaterial, the sequence of which contains alternating 
hydrophilic and hydrophobic amino acid residues. Paclitaxel 
is a hydrophobic antitumor drug that is poorly soluble in 
water. After stirring for 48 hours, PTX in RADA16 solu-
tion was changed to a colloidal suspension, while the same 
component in pure water was still clear, and a significant 
amount of PTX powder was visible (Figure 1). The data 
suggested that RADA16 interacted with PTX in aqueous 
solution.   Figure 2A and C showed the typical morphology of 
RADA16, which consisted of multiple cross-linked nanofibers 
that were 21.5 ± 3.3 nm in width and 2.2 ± 0.2 nm in height. 
After   stirring with PTX for 48 hours, the morphology of 
RADA16 changed. Some bulged nanofibers and aggregates 
could be seen (Figure 2B and D), and the width and height 
of those nanofibers were 45.3 ± 10.6 nm and 5.6 ± 2.3 nm, 
respectively. Some PTX particles coated by peptide nanofi-
bers were also observed (Figure 2B and D). From the circu-
lar dichroism analysis, the RADA16 peptide had a typical 
β-sheet structure (minimum molar ellipticity at 215–217 nm 
and maximum at 195–206 nm), with 50.6% β-sheet content 
(Figure 3 and Table 1, S (r) + S [d]) according to the CDPro 
software analysis.19 However, when RADA16 was stirred 
with PTX for 48 hours, there was an approximately 18.4% 
decrease in the β-sheet content and a 19.8% increase in 
the unordered structure content. Dynamic light scattering 
measurements showed that the diameter of nanofibers from 
a pure RADA16 solution was in the range of 10–50 nm. 
When PTX was stirred with 0.5% and 1% RADA16 solu-
tion, the mean particle sizes were 2744.7 ± 551.3 nm and 
2569.4 ± 434.9 nm, respectively, but there was no differ-
ence between the 0.5% and 1% RADA16 solution groups 
(  Figure 4). When PTX was stirred with Milli-Q water, the 
mean particle size was over 6 µm, and dynamic light scat-
tering measurements could not be conducted.
The circular dichroism data showed that the β-sheet struc-
ture of RADA16 was impaired to some extent by the addition 
of PTX, a result that was in accordance with the change in 
morphology on atomic force microscopy. The particle size 
of PTX was obviously decreased in the RADA16 solution 
compared with that in the water. All of the data indicated 
that RADA16 did not simply mix with PTX but rather inter-
acted with it. As illustrated in Figure 5, RADA16 consists 
of repeated sequences of Arg-Ala-Asp-Ala, in which Arg 
and Asp are hydrophilic amino acid residues and Ala is a 
hydrophobic amino acid residue; the β-sheet structure of 
the peptide therefore had both hydrophobic and hydrophilic 
regions.15 Because PTX is a typical hydrophobic compound, 
the hydrophobic regions of peptide would be adsorbed to 
the hydrophobic surface of separated PTX particles under 
Figure 1 After stirring for 48 hours, paclitaxel 1 mg/mL in pure water was still clear 
(left). however, the same concentration of paclitaxel in 0.5% rADA16 aqueous 
solution was changed to a colloidal suspension (right).
AB
C
1000 nm 1000 nm
500 nm 500 nm
D
Figure  2  Morphology  of  rADA16  peptide  and  rADA16-PTX  suspension. 
(A and C) Nanofibers in RADA16 solution. (B and D) Nanofibers in RADA16-
PTX suspension. It can be seen that some PTX particles were coated by rADA16 
nanofibers (black arrowhead).
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stirring, a phenomenon that resulted in the impaired β-sheet 
structure of RADA16 shown in the circular dichroism data. 
The atomic force microscopy images showed that there were 
many bulged RADA16 nanofibers, which may have resulted 
from PTX molecules that were incorporated with nanofibers 
or from the aggregation of nanofibers induced by hydropho-
bic interactions. The data indicate that the self-assembling 
peptide and PTX could interact with each other and that the 
amphiphilic peptide was able to stabilize hydrophobic drugs 
in aqueous solution, a finding that was in agreement with 
previous reports.20–22 This type of interaction also helps to 
increase the solubility of PTX and decrease the mean particle 
size of PTX in RADA16 solution under stirring. Therefore, 
the RADA16-PTX suspension could potentially be injected 
into the body with a syringe needle. These results indicated 
that PTX molecules and particles can coexist in RADA16-
PTX suspension, and stabilized PTX can be obtained in 
this system. However, further investigation is necessary to 
determine the percentage of each state in the complexes.
characterization of rADA16-PTX 
hydrogel formation
The gelation of RADA16-PTX suspension was characterized 
by rheometry. As in previous reports, the RADA16 solution 
was able to form a hydrogel in ionic environments, such as 
phosphate-buffered saline, physiological saline, and body 
fluid. However, could the RADA16-PTX suspension gel 
under physiological conditions? The test was performed at 
37°C, and phosphate-buffered saline was used to simulate 
body fluid. The storage modulus (G′) and loss modulus 
(G″) responded to the elasticity and viscosity of materials, 
  respectively. As shown in Figure 6, the frequency sweep 
indicated that the value of the storage modulus (G′) in the 
RADA16-PTX suspension was larger than that of the loss 
modulus (G″) both in 0.5% and 1% RADA16, and all of the 
low values (,10 Pa) for the storage and loss moduli were typi-
cal for low viscosity systems with a low degree of elasticity. 
With the addition of medium, significant changes occurred, ie, 
the storage and loss moduli increased. The storage modulus 
of 0.5% RADA16 was over 300 Pa and that of 1% RADA16 
was over 1000 Pa, whereas the original values for both 0.5% 
and 1% RADA16 were under 10 Pa. The great increase in the 
storage modulus suggested the formation of a strong hydrogel. 
At the mean time, it was observed that the storage modulus 
of 0.5% RADA16 hydrogel was much lower than that of the 
1% RADA16 hydrogel, which indicated that the concentration 
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Figure 3 secondary structure of rADA16 and rADA16 with incorporated paclitaxel. rADA16 peptide had a typical β-sheet structure. however, when paclitaxel was 
incorporated with rADA16, there was an obvious decrease in β-sheet structure.
Table 1 The calculated secondary structure fractions of peptide
Items Secondary structure fractions (%)
H (r) H (d) S (r) S (d) Turn Unrd
rADA16 0.4 1.9 33.8 16.8 20.4 26.7
rADA16-PTX 0.2 3.4 27.1 14.2 21.8 33.3
Abbreviations: h (r), regular α-helix; h (d), distorted α-helix; s (r), regular β-strand; 
s (d), distorted β-strand; Turn, β-turn structure; Unrd, unordered structure.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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of peptide had a positive correlation with the elasticity of the 
hydrogel. The results demonstrated that the RADA16-PTX 
suspension could form a highly elastic hydrogel under physi-
ological conditions. As an in situ forming gel drug delivery 
system, the ideal vehicle should be an injectable solution in 
vitro and change to a gel in vivo. RADA16 was able to form 
a hydrogel rapidly under physiological conditions without 
heating or chemical reaction, making it a favorable vehicle 
for drug delivery.
In vitro PTX release from rADA16-PTX 
hydrogel
Paclitaxel is a hydrophobic drug that is poorly soluble in 
water. To maintain sink conditions throughout the release 
Ac-RADARADARADARADA-CONH2
5 nm
1.3 nm
PTX
Hydrophobic face
Hydrophilic face
Figure 5 schematic representation of the interaction between rADA16 peptides and PTX. All alanine residues are present on the hydrophobic face of the rADA16 β-sheet, 
and the hydrophilic face consists of alternating arginine and aspartic acid residues (carbon, white; oxygen, red; nitrogen, blue; hydrogen, gray). 
Abbreviation: PTX, paclitaxel.
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Figure 4 Size distribution of pure RADA16 solution and RADA16-PTX suspension with different peptide concentrations. There was no significant difference between the 
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process, sodium dodecyl sulfate was added to the release 
medium to increase the solubility of PTX.5 The release was 
observed over a period of five days. As shown in Figure 7B, 
the RADA16 -PTX suspension could form a milky-white gel 
in phosphate-buffered saline, and the volume of hydrogel 
was obviously reduced over the release time. The resulting 
release profiles of PTX from the RADA16-PTX hydrogels 
are shown in Figure 7A. When a hydrogel was prepared with 
1% RADA16, approximately 40%–45% of incorporated PTX 
was released from the hydrogel within the first day, with a 
half-release time of 24–30 hours. In contrast, more than 60% 
of the PTX was released from the hydrogel within one day for 
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Figure 6 Frequency sweep of rADA16-PTX hydrogel in rheological analysis. (A) 0.5% rADA16-PTX and (B) 1% rADA16-PTX. The results showed that the storage 
modulus of 0.5% rADA16-PTX hydrogel was much lower than that of 1% rADA16-PTX hydrogel.
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the 0.5% RADA16 hydrogel, and the half-release time was 
8–10 hours. These results clearly demonstrated that a higher 
concentration of peptide in the hydrogel produced slower 
drug release rates. The initial burst effect was lower for the 
1% RADA16 hydrogel compared with the 0.5% RADA16 
hydrogel, and an increase in peptide concentration slowed 
the release rates of the loaded drug, resulting in a longer 
half-release time for the PTX. The atomic force microscopic 
image showed that many nanoparticles were present in the 
supernatant of the release medium (Figure 8A), and the 
width and height of the nanoparticles were 83.1 ± 30.3 nm 
and 4.9 ± 2.9 nm, respectively. However, sodium dodecyl 
sulfate was also an amphiphilic molecule, which might form 
assemblies in aqueous solution. Thus, an additional atomic 
force microscopy test with only sodium dodecyl sulfate in 
the release medium was performed to verify this result. The 
resulting images showed that sodium dodecyl sulfate was 
obviously accumulated on the surface of mica, and no similar 
size of nanoparticles formed (data not shown). These data 
suggest that PTX was encapsulated in peptide nanofibers and 
that RADA16-PTX nanoparticles were formed in the release 
process. A schematic representation of a possible model for 
PTX release from the PTX-RADA16 hydrogel is shown in 
Figure 8B. Considering the data from morphology and rheol-
ogy analysis, it was found that the higher concentration of 
peptide solution had more cross-linked nanofibers and led 
to the formation of a more elastic hydrogel. Because hydro-
gel formed from a higher concentration of peptide showed 
increased stability with a higher density of nanofibers and 
smaller sizes of pores, the probability of specific interactions 
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between PTX and peptide nanofibers and diffusion hindrance 
was increased, yielding a decrease in the diffusivity of PTX 
and finally resulting in slower drug release rates.15,16 These 
results suggested that the release rates of PTX can be con-
trolled by changing the peptide concentration, so the release 
time could be extended by adding a greater amount of peptide 
in future studies. In addition, the addition of sodium dodecyl 
sulfate as a surfactant can increase the release rates of PTX 
from the hydrogel, an effect that would be caused by the 
increased degradation rates of the RADA16 peptide.
Inhibition of rADA16-PTX hydrogel  
on the growth of tumor cells
As an antiproliferation drug, PTX is a potent inhibitor of 
angiogenesis, cell migration, and collagenase production. 
Because it has been demonstrated that PTX has significant 
antitumor activity against various solid tumors, including 
breast cancer, the human breast cancer cell line MDA-
MB-435S was used to study the antitumor efficiency of 
the RADA16-PTX hydrogel. As in previous reports, the 
antiproliferative activity of the complex was dependent on 
the concentration of PTX.2 To simulate the in vivo situation 
and optimize the antitumor test, PTX10 µg was administered 
to each well of the 96-well plate, and the culture medium 
was changed every day. In our study, the data showed that 
single use of RADA16 produced no inhibition of tumor cell 
proliferation, while the RADA16-PTX hydrogel inhibited 
growth of tumor cells effectively. As shown in Figure 9, there 
was no significant difference in cell viability rates between 
the PTX-treated group and both RADA16-PTX-treated 
groups at day 1. At day 3, there was a significant difference 
between the PTX group and the 1% RADA16-PTX group, 
but there was no significant difference between the 0.5% and 
1% RADA16-PTX groups. At days 5 and 7, compared with 
the PTX group, both RADA16-PTX groups demonstrated 
lower cell viability rates, and the cell viability rate in the 1% 
RADA16-PTX group was significantly lower than that in the 
0.5% RADA16-PTX group. These data suggest that PTX and 
0.5% RADA16-PTX had poor ability to inhibit cell growth 
after days 3 and 5, respectively, whereas 1% RADA16-PTX 
hydrogel maintained relatively high inhibitory activity even 
at day 7. It was concluded that the RADA16 hydrogel could 
control release of PTX effectively and that a higher concentra-
tion of peptide hydrogel resulted in an increased release time 
for PTX. This result was in accordance with those from the 
in vitro release test. The fluorescence images showed that 
the tumor cells in the RADA16 group continued to proliferate 
over the course of the observed days (Figure 10). By contrast, 
in the PTX group and both RADA16-PTX groups, only a few 
cells could be seen at day 3, which indicated that cell prolif-
eration was inhibited by PTX. However, the number of tumor 
cells in the PTX group was slightly higher than that in both 
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RADA16-PTX groups. At day 5, in comparison with the 1% 
RADA16-PTX group, more tumor cells were observed in the 
PTX and 0.5% RADA16-PTX groups. At day 7, compared 
with previous days, an increased number of tumor cells was 
observed in the PTX group and both RADA16-PTX groups, 
but fewer cells were seen in the 1% RADA16-PTX group than 
those in the PTX group and the 0.5% RADA16-PTX group. 
It was concluded that the 1% RADA16-PTX hydrogel had 
a longer lasting inhibitory effect on proliferation of tumor 
cells than did the other tested groups.
These results indicate that the self-assembling peptide 
system could be used to control the release of PTX. The 
release time of PTX from the hydrogel showed increased 
correlation with the concentration of peptide, and a more 
elastic hydrogel led to stronger interactions between the 
drug and the nanofibers, which decreased the diffusion 
rates of PTX and resulted in longer drug release times. The 
spontaneously gelling ability of RADA16-PTX suspension 
in an ionic environment provided the controlled release 
of PTX, which would increase the contact time of drug at 
the site of action and enhance the efficiency of therapy.5,23 
Because PTX cannot differentiate between cancer and 
normal cells, which may result in major toxicity to normal 
cells, the potential application of peptide hydrogel to the 
localized delivery of PTX might minimize the cytotoxicity 
and side effects. In addition, the self-assembling peptide 
was a biocompatible and biodegradable nanomaterial, which 
previous studies have reported to produce no toxic and 
immune response, and this material has been widely used 
for cell culture and injection into animals.24–26 Therefore, it 
suggested that this self-assembling peptide is a favorable 
vehicle for local PTX delivery as an in situ-forming 
hydrogel system. Nevertheless, further experiments are still 
needed to estimate the antitumor efficiency of the peptide-
PTX system in vivo.
Conclusion
In conclusion, this study found that the RADA16-PTX 
complex could form colloidal suspensions after magnetic 
stirring for 48 hours and that PTX was stabilized in 
RADA16-containing aqueous solutions. RADA16-PTX 
suspensions were able to form hydrogel spontaneously in 
ionic solutions. The RADA16-PTX hydrogel formed was 
of high elasticity and demonstrated controlled drug release 
properties. The RADA16 hydrogel prolonged the inhibitory 
effect of PTX on growth of breast cancer cells in vitro. 
This injectable, in situ-forming hydrogel system has great 
potential as a delivery vehicle for various hydrophobic drugs 
in future studies.
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